vs
Side-by-side financial comparison of Becton Dickinson (BDX) and State Street Corporation (STT). Click either name above to swap in a different company.
Becton Dickinson is the larger business by last-quarter revenue ($5.3B vs $3.7B, roughly 1.4× State Street Corporation). State Street Corporation runs the higher net margin — 20.4% vs 7.3%, a 13.1% gap on every dollar of revenue. On growth, State Street Corporation posted the faster year-over-year revenue change (7.5% vs -0.4%). State Street Corporation produced more free cash flow last quarter ($9.8B vs $549.0M). Over the past eight quarters, State Street Corporation's revenue compounded faster (8.1% CAGR vs 2.0%).
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
State Street Corporation is an American multinational financial services and bank holding company headquartered at One Congress Street in Boston. It is the second-oldest continuously operating U.S. bank, tracing its roots to Union Bank, chartered in 1792. As of the third quarter of 2025, State Street is one of the world's largest asset managers and custodians, with approximately US$5.4 trillion in assets under management and US$51.7 trillion under custody and administration.
BDX vs STT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3B | $3.7B |
| Net Profit | $382.0M | $747.0M |
| Gross Margin | 45.9% | — |
| Operating Margin | 10.5% | 25.0% |
| Net Margin | 7.3% | 20.4% |
| Revenue YoY | -0.4% | 7.5% |
| Net Profit YoY | 24.0% | -4.6% |
| EPS (diluted) | $1.34 | $2.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.3B | $3.7B | ||
| Q3 25 | $5.9B | $3.5B | ||
| Q2 25 | $5.5B | $3.4B | ||
| Q1 25 | $5.3B | $3.3B | ||
| Q4 24 | $5.2B | $3.4B | ||
| Q3 24 | $5.4B | $3.3B | ||
| Q2 24 | $5.0B | $3.2B | ||
| Q1 24 | $5.0B | $3.1B |
| Q4 25 | $382.0M | $747.0M | ||
| Q3 25 | $493.0M | $861.0M | ||
| Q2 25 | $574.0M | $693.0M | ||
| Q1 25 | $308.0M | $644.0M | ||
| Q4 24 | $303.0M | $783.0M | ||
| Q3 24 | $400.0M | $730.0M | ||
| Q2 24 | $487.0M | $711.0M | ||
| Q1 24 | $537.0M | $463.0M |
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
| Q4 25 | 10.5% | 25.0% | ||
| Q3 25 | 11.8% | 31.1% | ||
| Q2 25 | 16.0% | 25.8% | ||
| Q1 25 | 10.4% | 25.0% | ||
| Q4 24 | 8.8% | 28.1% | ||
| Q3 24 | 11.4% | 28.4% | ||
| Q2 24 | 12.1% | 28.6% | ||
| Q1 24 | 14.5% | 19.1% |
| Q4 25 | 7.3% | 20.4% | ||
| Q3 25 | 8.4% | 24.3% | ||
| Q2 25 | 10.4% | 20.1% | ||
| Q1 25 | 5.8% | 19.6% | ||
| Q4 24 | 5.9% | 22.9% | ||
| Q3 24 | 7.4% | 22.4% | ||
| Q2 24 | 9.8% | 22.3% | ||
| Q1 24 | 10.6% | 14.8% |
| Q4 25 | $1.34 | $2.41 | ||
| Q3 25 | $1.71 | $2.78 | ||
| Q2 25 | $2.00 | $2.17 | ||
| Q1 25 | $1.07 | $2.04 | ||
| Q4 24 | $1.04 | $2.43 | ||
| Q3 24 | $1.37 | $2.26 | ||
| Q2 24 | $1.68 | $2.15 | ||
| Q1 24 | $1.85 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $740.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $25.3B | $27.8B |
| Total Assets | $54.8B | $366.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $740.0M | — | ||
| Q3 25 | $641.0M | — | ||
| Q2 25 | $735.0M | — | ||
| Q1 25 | $667.0M | — | ||
| Q4 24 | $711.0M | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $2.3B | — |
| Q4 25 | $25.3B | $27.8B | ||
| Q3 25 | $25.4B | $27.6B | ||
| Q2 25 | $25.5B | $27.3B | ||
| Q1 25 | $25.2B | $26.7B | ||
| Q4 24 | $25.2B | $25.3B | ||
| Q3 24 | $25.9B | $25.8B | ||
| Q2 24 | $25.9B | $24.8B | ||
| Q1 24 | $25.6B | $24.4B |
| Q4 25 | $54.8B | $366.0B | ||
| Q3 25 | $55.3B | $371.1B | ||
| Q2 25 | $54.9B | $376.7B | ||
| Q1 25 | $54.5B | $372.7B | ||
| Q4 24 | $54.7B | $353.2B | ||
| Q3 24 | $57.3B | $338.5B | ||
| Q2 24 | $55.6B | $325.6B | ||
| Q1 24 | $54.2B | $338.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $657.0M | $10.0B |
| Free Cash FlowOCF − Capex | $549.0M | $9.8B |
| FCF MarginFCF / Revenue | 10.5% | 266.6% |
| Capex IntensityCapex / Revenue | 2.1% | 7.3% |
| Cash ConversionOCF / Net Profit | 1.72× | 13.44× |
| TTM Free Cash FlowTrailing 4 quarters | $2.6B | $10.8B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $657.0M | $10.0B | ||
| Q3 25 | $1.4B | $7.9B | ||
| Q2 25 | $1.2B | $-8.4B | ||
| Q1 25 | $164.0M | $2.4B | ||
| Q4 24 | $693.0M | $-7.4B | ||
| Q3 24 | $1.2B | $2.7B | ||
| Q2 24 | $1.3B | $-7.6B | ||
| Q1 24 | $514.0M | $-844.0M |
| Q4 25 | $549.0M | $9.8B | ||
| Q3 25 | $1.0B | $7.7B | ||
| Q2 25 | $1.0B | $-8.8B | ||
| Q1 25 | $35.0M | $2.2B | ||
| Q4 24 | $588.0M | $-7.7B | ||
| Q3 24 | $882.0M | $2.5B | ||
| Q2 24 | $1.1B | $-7.9B | ||
| Q1 24 | $380.0M | $-1.1B |
| Q4 25 | 10.5% | 266.6% | ||
| Q3 25 | 17.0% | 216.0% | ||
| Q2 25 | 19.0% | -254.1% | ||
| Q1 25 | 0.7% | 66.1% | ||
| Q4 24 | 11.4% | -225.1% | ||
| Q3 24 | 16.2% | 75.9% | ||
| Q2 24 | 22.4% | -246.2% | ||
| Q1 24 | 7.5% | -34.2% |
| Q4 25 | 2.1% | 7.3% | ||
| Q3 25 | 6.0% | 6.9% | ||
| Q2 25 | 3.2% | 9.3% | ||
| Q1 25 | 2.4% | 6.9% | ||
| Q4 24 | 2.0% | 7.3% | ||
| Q3 24 | 5.4% | 7.2% | ||
| Q2 24 | 3.6% | 6.7% | ||
| Q1 24 | 2.7% | 7.3% |
| Q4 25 | 1.72× | 13.44× | ||
| Q3 25 | 2.75× | 9.18× | ||
| Q2 25 | 2.12× | -12.18× | ||
| Q1 25 | 0.53× | 3.72× | ||
| Q4 24 | 2.29× | -9.49× | ||
| Q3 24 | 2.94× | 3.71× | ||
| Q2 24 | 2.66× | -10.75× | ||
| Q1 24 | 0.96× | -1.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
STT
| Other | $2.2B | 59% |
| Investment Management | $729.0M | 20% |
| Management Services | $662.0M | 18% |
| Other Fee Revenue | $56.0M | 2% |
| Securities Financing Services | $54.0M | 1% |
